Table 3 Pim kinase inhibitors used in preclinical and clinical (bold) trials for AML
From: Targeting Pim kinases in hematological cancers: molecular and clinical review
Acute Myeloid Leukemia | Target(s) | Type | Clinical Trials | |
|---|---|---|---|---|
AZD1208 | pan-Pim | Single | AML | NCT01489722 |
AZD1208 + Daunorubicin (etoposide, and mitoxantrone) | pan-Pim + Topoisomerase 2 | Dual-therapy | Preclinical | – |
AZD1208 + SCIO-469 | pan-Pim + p38 | Dual-therapy | Preclinical | – |
AZD1208 + MK2206 (AZD5363) | pan-Pim + AKT | Dual-therapy | Preclinical | – |
AZD1208 + AZD2014 (AZD8055) | pan-Pim + mTOR | Dual-therapy | Preclinical | – |
AZD1897 | pan-Pim | Single | Preclinical | – |
EC-70124 | pan-kinase (Pim, FLT3, JAK, SYK) | Single | Preclinical | – |
ETH-155008 | Pim3 FLT3 CDK4/6 | Triple inhibitor (FLT3, Pim-3 and CDK4/6) Monotherapy | AML | NCT04840784 |
ETP-45299 + GDC-0941 | Pim1 + PI3K | Dual-therapy | Preclinical | – |
K00135 | Pim1/Pim2 | Single | Preclinical | – |
K00486 | Pim1/Pim2 | Single | Preclinical | – |
PIM447 | pan-Pim | Single | AML | NCT02078609 |
SEL24/MEN1703 | PIM FLT3 | Double inhibitor (FLT3, Pim) Monotherapy | AML | NCT03008187 |
SGI-1776 | pan-Pim | Single | Yes | – |
Uzansertib | Pan-Pim | Single | AML | NCT02587598 |